drugset / Trial / NCT06981078
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Timeline
- Start
- 2025-07-02
- Primary completion
- 2027-10
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Verekitug | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | Verekitug | Monoclonal antibody | 400 mg | Subcutaneous |